Abstract:Osteoarthritis (OA) is a degenerative joint disease, characterized by infiltration of monocytes into the synovial joint which promotes inflammation, stiffness, joint swelling, cartilage degradation and further bone destruction. The leaves of Ocimum forskolei have been used for inflammation-related disease management in traditional medicine. Additionally, the downregulation of NF-κB and the MMP/TIMP-1 ratio has been shown to protect against OA. The LC-HR-MS metabolic analysis of Ocimum yielded 19 putative compounds, among which ursolic acid (UA) was detected. Ursolic acid possesses significant anti-inflammatory effects and has been reported to downregulate oxidative stress and inflammatory biomarkers. It was tested on rats in a model of intra-articular carrageenan injection to investigate its efficacy on osteoarthritis progression. The UA emulgel exerted chondroprotective, analgesic and local anaesthetic efficacies confirmed via histopathological investigation and radiographical imaging. A network pharmacology followed by molecular docking highlighted TNF-α, TGF-β and NF-κB as the top filtered genes. Quantitative real-time PCR analysis showed that UA significantly attenuated serum levels of TNF-α , IL-1β , NF-κB , MMP-9 / TIMP-1 and elevated levels of TGF-β . Taken together, these results suggest that UA could serve as a functional food-derived phytochemical with a multi-targeted efficacy on progression of OA, regulating the immune and inflammatory responses, particularly, attenuating chondrocytes degeneration via suppression of NF-κB and MMP-9 / TIMP-1 . Accordingly, UA might be a promising alternative to conventional therapy for safe, easily applicable and effective management of OA.

What problem does this paper attempt to address?

The paper primarily explores the effects of Ursolic Acid (UA) on Osteoarthritis (OA) and its potential mechanisms. Specifically, the study aims to address the following key issues: 1. **Verify whether Ursolic Acid can inhibit the NF-κB signaling pathway and regulate the ratio of Matrix Metalloproteinase-9 (MMP-9) to Tissue Inhibitor of Metalloproteinases-1 (TIMP-1)**: The paper points out that inhibiting the NF-κB signaling pathway and adjusting the MMP-9/TIMP-1 ratio can protect OA patients from disease progression. Therefore, the study evaluated the effects of Ursolic Acid in this regard. 2. **Explore the multi-target effects of Ursolic Acid on OA treatment**: The study analyzed the mechanisms of Ursolic Acid in OA treatment through network pharmacology, with a particular focus on its regulation of immune and inflammatory responses, especially by inhibiting NF-κB and MMP-9/TIMP-1 to slow down the degeneration of chondrocytes. 3. **Evaluate the efficacy of Ursolic Acid emulgel in an OA model**: Using an experimental animal model (acute monoarthritis model induced by intra-articular injection of carrageenan in rat knee joints), the study tested the effects of Ursolic Acid emulgel (UA-emulgel) in alleviating OA symptoms. In summary, the study attempts to demonstrate that Ursolic Acid, as a natural product, has the potential to be a new strategy for OA treatment, particularly through its regulation of the NF-κB signaling pathway and MMP-9/TIMP-1 ratio, as well as its clinical application potential in alleviating OA symptoms as an emulgel.

Ursolic acid inhibits NF-κB signaling and attenuates MMP-9/TIMP-1 in progressive osteoarthritis: a network pharmacology-based analysis